We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sanofi Offers Takeover of Aventis for $65 Billion

By Biotechdaily staff writers
Posted on 05 May 2004
In a move that would create the world's third largest pharmaceutical company and the largest in Europe, Sanofi-Synthelabo (Paris, France) has made a friendly takover bid of U.S.$65 billion in cash and stock for Aventis (Strasbourg, France), which has been approved by the Aventis board.

The new company will be called Sanofi-Aventis and will rank only behind Pfizer and GaxoSmithKline in global pharmaceutical sales. More...
The offer followed the news that Novartis (Basel, Switzerland) was interested in a merger with Sanofi-Synthelabo and will ensure that France will be home to a large pharmaceutical company, as desired by the French government.

To avoid regulatory concerns, Sanofi had earlier declared it would sell two blood-thinning drugs, Fraxiparine and Arixtra, and also the manufacturing plant in France where they are manufactured. The merger has already been approved by the European Commission.




Related Links:
Sanofi-Synthelabo
Aventis

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.